FORMULATION ARTICLES

FORMULATION VIDEOS

Nutcracker Therapeutics’ Oreanna Thomas shares her takeaways from a pre-IND meeting for one of the company’s mRNA therapeutic candidates.

There are many different criteria for selecting a CDMO for your mRNA products. Arcturus’ Qian Ruan explains that a product’s stage of development and the specific needs inherent to that phase of development should be an important guide for companies today, especially given the expansion of the outsourcing sector and the wide range of capabilities.

Discover how advanced ionizable LNP formulations and scalable manufacturing strategies can accelerate the development and clinical translation of personalized cancer vaccines.

In this Advancing RNA Live clip, NanoVation’s Dominik Witzigmann and Stealth Co’s John Zuris break down the scientific advancements we’re seeing for each of an LNP’s components (i.e., the ionizable lipid, helper lipid, and PEG), albeit with the caveat that, with these advancements, Freedom to Operate (FTO) continues to grow increasingly complicated.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS